Showing 1 - 6 results of 6 for search 'Anthony B. El-Khoueiry', query time: 0.03s Refine Results
  1. 1
    IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

    IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer by Stephen P. Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry, Andrew X. Zhu

    Published 2021-07-01
    Get full text
    Article
  2. 2
    Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

    Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the... by Anthony B. El-Khoueiry, Tim Meyer, Ann-Lii Cheng, Lorenza Rimassa, Suvajit Sen, Steven Milwee, Robin Kate Kelley, Ghassan K. Abou-Alfa

    Published 2022-04-01
    Get full text
    Article
  3. 3
    Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

    Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040) by Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

    Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma by Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa

    Published 2021-12-01
    Get full text
    Article
  5. 5
    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors by Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry

    Published 2022-10-01
    Get full text
    Article
  6. 6
    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma by Amaia Lujambio, Thomas Yau, Lipika Goyal, Andrew X Zhu, Ignacio Melero, Tim F Greten, Ann-Lii Cheng, Bruno Sangro, David J Pinato, Peter R Galle, Ghassan K Abou-Alfa, Austin G Duffy, Anthony B. El-Khoueiry, Richard S Finn, Aiwu Ruth He, Ahmed O Kaseb, Robin Kate Kelley, Riccardo Lencioni, Donna Mabry Hrones, Roberto I Troisi, Andrea Wilson Woods

    Published 2021-09-01
    Get full text
    Article

Search Tools: